BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 25771900)

  • 1. Prognostic significance of TIMP-2, MMP-2, and MMP-9 on high-grade serous ovarian carcinoma using digital image analysis.
    Desmeules P; Trudel D; Turcotte S; Sirois J; Plante M; Grégoire J; Renaud MC; Orain M; Têtu B; Bairati I
    Hum Pathol; 2015 May; 46(5):739-45. PubMed ID: 25771900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Visual and automated assessment of matrix metalloproteinase-14 tissue expression for the evaluation of ovarian cancer prognosis.
    Trudel D; Desmeules P; Turcotte S; Plante M; Grégoire J; Renaud MC; Orain M; Bairati I; Têtu B
    Mod Pathol; 2014 Oct; 27(10):1394-404. PubMed ID: 24603589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
    Sakata K; Shigemasa K; Nagai N; Ohama K
    Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the hepatocellular carcinomas].
    Wei QY; Wu YQ; Fan SQ
    Hunan Yi Ke Da Xue Xue Bao; 2003 Jun; 28(3):212-6. PubMed ID: 14653069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
    Hu XX; Li L; Li DR; Zhang W; Cheng XQ; Zhang JQ; Tang BJ
    Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serous and mucinous ovarian tumors express different profiles of MMP-2, -7, -9, MT1-MMP, and TIMP-1 and -2.
    Brun JL; Cortez A; Commo F; Uzan S; Rouzier R; Daraï E
    Int J Oncol; 2008 Dec; 33(6):1239-46. PubMed ID: 19020757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significant relationship of matrix metalloproteinase 9 with nuclear grade and prognostic impact of tissue inhibitor of metalloproteinase 2 for incidental clear cell renal cell carcinoma.
    Kawata N; Nagane Y; Hirakata H; Ichinose T; Okada Y; Yamaguchi K; Takahashi S
    Urology; 2007 Jun; 69(6):1049-53. PubMed ID: 17572184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression.
    Torng PL; Mao TL; Chan WY; Huang SC; Lin CT
    Gynecol Oncol; 2004 Feb; 92(2):559-67. PubMed ID: 14766248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
    Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T
    Cancer Lett; 2006 May; 236(1):125-32. PubMed ID: 15982804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Expression of matrix metaloproteinase and tissue inhibitors in ovarian tumors].
    Cai W; Song JD
    Ai Zheng; 2002 Jan; 21(1):91-4. PubMed ID: 12500407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of matrix metalloproteinases and related tissue inhibitors in the cyst fluids of ovarian mucinous neoplasms.
    Furuya M; Ishikura H; Kawarada Y; Ogawa Y; Sakuragi N; Fujimoto S; Yoshiki T
    Gynecol Oncol; 2000 Aug; 78(2):106-12. PubMed ID: 10926788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gelatinase B expression as a prognostic factor in patients with stage II/III rectal carcinoma treated by postoperative adjuvant therapy.
    Unsal D; Akyurek N; Uner A; Erpolat OP; Han U; Akmansu M; Mentes BB; Dursun A
    Am J Clin Oncol; 2008 Feb; 31(1):55-63. PubMed ID: 18376229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matrix metalloproteinases 2 and 9 and their tissue inhibitors in low malignant potential ovarian tumors.
    Määttä M; Santala M; Soini Y; Talvensaari-Mattila A; Turpeenniemi-Hujanen T
    Tumour Biol; 2004; 25(4):188-92. PubMed ID: 15557756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.
    Liebscher CA; Prinzler J; Sinn BV; Budczies J; Denkert C; Noske A; Sehouli J; Braicu EI; Dietel M; Darb-Esfahani S
    Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Expression and significance of matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase in non-melanoma skin cancer].
    Fu XR; Zhang C; Chen CY; Zhang L; Wang LX; Wang BH; Liu XY; Zhang MZ
    Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):369-73. PubMed ID: 22883459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression and prognostic significance of fibronectin and matrix metalloproteases in breast cancer metastasis.
    Fernandez-Garcia B; Eiró N; Marín L; González-Reyes S; González LO; Lamelas ML; Vizoso FJ
    Histopathology; 2014 Mar; 64(4):512-22. PubMed ID: 24117661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of MMP-2, -7, -9, MT1-MMP and TIMP-1 and -2 has no prognostic relevance in patients with advanced epithelial ovarian cancer.
    Brun JL; Cortez A; Lesieur B; Uzan S; Rouzier R; Daraï E
    Oncol Rep; 2012 Apr; 27(4):1049-57. PubMed ID: 22200690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HtrA1 expression and the prognosis of high-grade serous ovarian carcinoma: a cohort study using digital analysis.
    Gagné A; Têtu B; Orain M; Turcotte S; Plante M; Grégoire J; Renaud MC; Bairati I; Trudel D
    Diagn Pathol; 2018 Aug; 13(1):57. PubMed ID: 30131069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased matrix metalloproteinases 2 and 9 and tissue inhibitor of matrix metalloproteinase 2 expression is associated with progression from vulvar intraepithelial neoplasia to invasive carcinoma.
    Määttä M; Santala M; Soini Y; Turpeenniemi-Hujanen T; Talvensaari-Mattila A
    Acta Obstet Gynecol Scand; 2010 Mar; 89(3):380-4. PubMed ID: 20109015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma level of tissue inhibitor of matrix metalloproteinase-1 but not that of matrix metalloproteinase-8 predicts survival in head and neck squamous cell cancer.
    Pradhan-Palikhe P; Vesterinen T; Tarkkanen J; Leivo I; Sorsa T; Salo T; Mattila PS
    Oral Oncol; 2010 Jul; 46(7):514-8. PubMed ID: 20371206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.